source
- Post-Hoc: Lilly gets more secretive and hides Phase 1 pipelineEli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings pres…Endpoints · 2mo ago↗ source
- Replimune takes third swing at cancer drug approval following ‘productive’ FDA talksA twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.BioPharma Dive · 2mo ago↗ source
- AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…